艾利索三萜在细胞膜上表现出三重调节机制以克服癌症多药耐药。

IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL
Drug Design, Development and Therapy Pub Date : 2025-06-26 eCollection Date: 2025-01-01 DOI:10.2147/DDDT.S521116
Jing-Yi Chen, Ying-Tzu Chang, Yu-Cheng Ho, Yu-Ning Teng
{"title":"艾利索三萜在细胞膜上表现出三重调节机制以克服癌症多药耐药。","authors":"Jing-Yi Chen, Ying-Tzu Chang, Yu-Cheng Ho, Yu-Ning Teng","doi":"10.2147/DDDT.S521116","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose and study design: </strong>Multi-drug resistance (MDR) in cancer significantly hinders effective treatment, leading to poor patient outcomes. The study investigates the potential of natural compounds, Alisol B 23-acetate (B23) and Alisol A 24-acetate (A24), to reverse MDR through various mechanisms on cancer cell membranes.</p><p><strong>Results: </strong>Cytotoxicity assays established non-toxic concentrations of B23 and A24, which were then tested in drug-sensitive and drug-resistant cancer cell lines with or without chemotherapeutic drugs. Both compounds significantly enhanced reactive oxygen species (ROS) production and apoptosis in HepG2/VIN MDR cells while preserving cell membrane integrity. They also improved membrane fluidity and inhibited the function of P-glycoprotein (P-gp) efflux transporters in both HepG2/VIN and <i>ABCB1</i>/Flp-In<sup>TM</sup>-293, leading to increased drug accumulation. Molecular docking studies revealed that B23 and A24 interact with distinct binding sites on P-gp, demonstrating allosteric and competitive inhibition.</p><p><strong>Conclusion: </strong>B23 and A24 effectively reverse cancer MDR by (1) modulating ROS levels and inducing apoptosis, (2) maintaining membrane integrity but improving membrane fluidity, and (3) inhibiting drug efflux by membrane transporters. These findings provide a promising basis for developing new therapeutic strategies to combat MDR in cancer, highlighting the potential use of these natural product derivatives in adjunctive cancer therapy.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"5471-5488"},"PeriodicalIF":4.7000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12208304/pdf/","citationCount":"0","resultStr":"{\"title\":\"Alisol Triterpenoids Exhibit Triple Modulatory Mechanisms on the Cell Membrane to Overcome Cancer Multidrug Resistance.\",\"authors\":\"Jing-Yi Chen, Ying-Tzu Chang, Yu-Cheng Ho, Yu-Ning Teng\",\"doi\":\"10.2147/DDDT.S521116\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose and study design: </strong>Multi-drug resistance (MDR) in cancer significantly hinders effective treatment, leading to poor patient outcomes. The study investigates the potential of natural compounds, Alisol B 23-acetate (B23) and Alisol A 24-acetate (A24), to reverse MDR through various mechanisms on cancer cell membranes.</p><p><strong>Results: </strong>Cytotoxicity assays established non-toxic concentrations of B23 and A24, which were then tested in drug-sensitive and drug-resistant cancer cell lines with or without chemotherapeutic drugs. Both compounds significantly enhanced reactive oxygen species (ROS) production and apoptosis in HepG2/VIN MDR cells while preserving cell membrane integrity. They also improved membrane fluidity and inhibited the function of P-glycoprotein (P-gp) efflux transporters in both HepG2/VIN and <i>ABCB1</i>/Flp-In<sup>TM</sup>-293, leading to increased drug accumulation. Molecular docking studies revealed that B23 and A24 interact with distinct binding sites on P-gp, demonstrating allosteric and competitive inhibition.</p><p><strong>Conclusion: </strong>B23 and A24 effectively reverse cancer MDR by (1) modulating ROS levels and inducing apoptosis, (2) maintaining membrane integrity but improving membrane fluidity, and (3) inhibiting drug efflux by membrane transporters. These findings provide a promising basis for developing new therapeutic strategies to combat MDR in cancer, highlighting the potential use of these natural product derivatives in adjunctive cancer therapy.</p>\",\"PeriodicalId\":11290,\"journal\":{\"name\":\"Drug Design, Development and Therapy\",\"volume\":\"19 \",\"pages\":\"5471-5488\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12208304/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Design, Development and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/DDDT.S521116\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S521116","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

目的和研究设计:癌症多药耐药(MDR)严重阻碍有效治疗,导致患者预后不良。本研究探讨了天然化合物Alisol B23 -acetate (B23)和Alisol A 24-acetate (A24)通过多种作用于癌细胞细胞膜的机制逆转MDR的潜力。结果:细胞毒性试验确定了B23和A24的无毒浓度,然后在有或没有化疗药物的药物敏感和耐药癌细胞系中进行了测试。这两种化合物都能显著增强HepG2/VIN MDR细胞的活性氧(ROS)产生和凋亡,同时保持细胞膜的完整性。它们还改善了细胞膜流动性,抑制了HepG2/VIN和ABCB1/ flip - intm -293中p-糖蛋白(P-gp)外排转运蛋白的功能,导致药物积累增加。分子对接研究表明,B23和A24与P-gp上不同的结合位点相互作用,表现出变构和竞争抑制。结论:B23和A24通过(1)调节ROS水平并诱导细胞凋亡,(2)维持膜完整性但提高膜流动性,(3)抑制膜转运体的药物外排,有效逆转肿瘤MDR。这些发现为开发对抗癌症耐多药的新治疗策略提供了有希望的基础,突出了这些天然产物衍生物在辅助癌症治疗中的潜在用途。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Alisol Triterpenoids Exhibit Triple Modulatory Mechanisms on the Cell Membrane to Overcome Cancer Multidrug Resistance.

Purpose and study design: Multi-drug resistance (MDR) in cancer significantly hinders effective treatment, leading to poor patient outcomes. The study investigates the potential of natural compounds, Alisol B 23-acetate (B23) and Alisol A 24-acetate (A24), to reverse MDR through various mechanisms on cancer cell membranes.

Results: Cytotoxicity assays established non-toxic concentrations of B23 and A24, which were then tested in drug-sensitive and drug-resistant cancer cell lines with or without chemotherapeutic drugs. Both compounds significantly enhanced reactive oxygen species (ROS) production and apoptosis in HepG2/VIN MDR cells while preserving cell membrane integrity. They also improved membrane fluidity and inhibited the function of P-glycoprotein (P-gp) efflux transporters in both HepG2/VIN and ABCB1/Flp-InTM-293, leading to increased drug accumulation. Molecular docking studies revealed that B23 and A24 interact with distinct binding sites on P-gp, demonstrating allosteric and competitive inhibition.

Conclusion: B23 and A24 effectively reverse cancer MDR by (1) modulating ROS levels and inducing apoptosis, (2) maintaining membrane integrity but improving membrane fluidity, and (3) inhibiting drug efflux by membrane transporters. These findings provide a promising basis for developing new therapeutic strategies to combat MDR in cancer, highlighting the potential use of these natural product derivatives in adjunctive cancer therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Drug Design, Development and Therapy
Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY
CiteScore
9.00
自引率
0.00%
发文量
382
审稿时长
>12 weeks
期刊介绍: Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信